Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01532232 · ClinicalTrials.gov registry record
Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Terminated
- Registry status
- 7
- Enrollment target
NCT01532232: Clinical Trial study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01532232 is a clinical trial that was terminated before completion, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01532232 was terminated before completion, sponsored by Memorial Sloan Kettering Cancer Center.
- TERMINATED
- Registry status
- 7 participants
- Enrollment target
Study Summary
Breast cancer patients who smoke, are at greater risk for treatment complications. The purpose of this study is to see if the researchers can find ways to help patients who have breast cancer quit smoking. They will compare two ways to help people quit smoking. Some patients will receive varenicline, a prescription medicine also known as Chantix,®. Other patients will receive a placebo drug. A placebo is an inactive substance that contains no medicine. All patients will receive smoking cessation counseling provided by our tobacco treatment specialists. They hope that what the researchers learn from this study will help us improve our smoking cessation treatment program for breast cancer patients.
Interventions
- DRUG placebo
- DRUG varenicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01532232
The ClinicalTrials.gov registry entry for NCT01532232 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01532232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01532232 about?
NCT01532232 is a clinical study titled "Tobacco Dependence in Breast Cancer Patients Trial of Varenicline (Chantix)". Breast cancer patients who smoke, are at greater risk for treatment complications. The purpose of this study is to see if the researchers can find ways to help patients who have breast cancer quit smoking. They will compare two ways to help people quit smoking. Some patients will receive varenicline...
What is the current status of trial NCT01532232?
This trial is currently terminated. The enrollment target is 7 participants. The study started on 2012-02. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01532232?
The interventions under investigation include: placebo (DRUG), varenicline (DRUG).
Who is sponsoring clinical trial NCT01532232?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.